Semaglutide 1mg sc weekly reduces the occurrence of major kidney disease events in patients with type 2 diabetes and chronic kidney disease
The FLOW Trial
Semaglutide 1mg sc weekly reduces the occurrence of major kidney disease events in patients with type 2 diabetes and chronic kidney disease